Related Experiment Video
Updated: Aug 14, 2026

Laser Capture Microdissection of Mouse Embryonic Cartilage and Bone for Gene Expression Analysis
Published on: December 18, 2019
New target genes for NOV/CCN3 in chondrocytes: TGF-beta2 and type X collagen
Jerome Lafont1, Claire Jacques, Gwenvael Le Dreau
1INSERM U515, Hôpital Saint-Antoine, Paris Cedex 12, France.
Unlabelled:
We studied the involvement of NOV/CCN3, whose function is poorly understood, in chondrocyte differentiation. NOV was found to upregulate TGF-beta2 and type X collagen and to act as a downstream effector of TGF-beta1 in ATDC5 and primary chondrocytes. Thus, NOV is a positive modulator of chondrogenesis.
Introduction:
NOV/CCN3 is a matricellular protein that belongs to the CCN family. A growing body of evidence indicates that NOV could play a role in cell differentiation, particularly in chondrogenesis. During chick embryo development, NOV expression is tightly regulated in cartilage, and a high expression of NOV has been associated with cartilage differentiation in Wilms' tumors. However, a precise role for NOV and potential target genes of NOV in chondrogenesis are unknown.
Materials And Methods:
ATDC5 cells and primary chondrocytes were either treated with NOV recombinant protein or transfected with a NOV-specific siRNA to determine, using quantitative RT-PCR, the effect of NOV on the expression of several molecules involved in chondrocyte differentiation. Stable ATDC5 clones expressing NOV were also established to show that NOV was a downstream effector of TGF-beta1.
Results:
We established that NOV/CCN3 expression increases in ATDC5 cells at early stages of chondrogenic differentiation and precedes the appearance of TGF-beta2 and of several chondrocytic markers such as SOX9 or type X collagen. When exogenously administered, NOV recombinant protein up-regulates TGF-beta2 and type X collagen mRNA levels both in ATDC5 cells and in primary mouse chondrocytes but does not influence SOX9 expression. This regulation also occurs at the endogenous level because downregulation of NOV expression is correlated with an inhibition of TGF-beta2 and type X collagen in primary chondrocytes. Furthermore, we found that NOV expression is downregulated when chondrocytes are exposed to TGF-beta1-dedifferentiating treatment in chondrocytes, further providing evidence that NOV may counteract TGF-beta1 effects on chondrocytes.
Conclusions:
This study provides the first characterization of two new targets of NOV involved in chondrocyte differentiation, shows that NOV acts with TGF-beta1 in a cascade of gene regulation, and indicates that NOV is a positive modulator of chondrogenesis.
Insights
NOV/CCN3 (Nov) protein promotes chondrocyte differentiation by upregulating TGF-beta2 and type X collagen. This study reveals Nov as a key positive modulator in chondrogenesis, acting downstream of TGF-beta1 signaling.
Area of Science:
- Cell Biology
- Developmental Biology
- Biochemistry
Background:
- NOV/CCN3 (Nov) is a matricellular protein implicated in cell differentiation, particularly chondrogenesis.
- NOV expression is regulated during cartilage development and associated with cartilage differentiation in tumors.
- The precise role and target genes of NOV in chondrogenesis remain largely unknown.
Purpose of the Study:
- To investigate the function of NOV/CCN3 in chondrocyte differentiation.
- To identify downstream targets of NOV during chondrogenesis.
- To elucidate the relationship between NOV and TGF-beta signaling in cartilage formation.
Main Methods:
- Quantitative RT-PCR was used to assess gene expression in ATDC5 cells and primary chondrocytes treated with NOV recombinant protein or NOV-specific siRNA.
- Stable ATDC5 cell lines expressing NOV were generated.
- The effect of NOV on TGF-beta1 signaling was investigated.
Main Results:
- NOV/CCN3 expression increased during early chondrogenic differentiation in ATDC5 cells, preceding markers like TGF-beta2 and type X collagen.
- Exogenous NOV upregulated TGF-beta2 and type X collagen mRNA in ATDC5 cells and primary chondrocytes.
- NOV downregulation inhibited endogenous TGF-beta2 and type X collagen, and NOV expression was reduced by TGF-beta1 treatment.
Conclusions:
- NOV/CCN3 positively modulates chondrogenesis.
- NOV/CCN3 upregulates TGF-beta2 and type X collagen, identifying them as novel targets.
- NOV acts as a downstream effector of TGF-beta1 in a gene regulatory cascade during chondrogenesis.
Related Concept Videos
TGF - β Signaling Pathway
Fibril-associated Collagen
For example, the type II collagen fibrils in cartilage have covalently bound type IX fibril-associated collagens at regular intervals. Other types of fibril-associated collagens are...
Canonical Wnt Signaling Pathway
Bone Remodeling and Repair
Growth of Cartilage and Bone Tissue
Catenins
Catenins in Cell Junctions
Catenins bind to cell adhesion molecules such as cadherins and link them to different cytoskeletal proteins depending on the type of cell junction. At the adherens...